Relay Therapeutics, Inc. (RLAY) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $12.92: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality; Negative price momentum.
Relay Therapeutics is a clinical-stage precision oncology company using its Dynamo Motion-Based Drug Design platform to develop small molecule inhibitors for cancer. The lead candidate zovegalisib (RLY-2608) is the first allosteric pan-mutant PI3Ka inhibitor, granted FDA... Read more
Sell if holding. Engine safety override at $12.92: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.1/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst cluster(7), semi cycle peak clear). Fails on weak momentum and earnings proximity 5d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinezovegalisib10-K Item 1A: 'We intend to develop zovegalisib and may develop our other current product candidates and future product candidates'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 8.3% daily ATR makes tight stops impractical. Position-size conservatively.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $12.92: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $12.02. Score 5.1/10, moderate confidence.
Take-profit target: $18.27 (+41.4% upside). Prior stop was $12.02. Stop-loss: $12.02.
Concentration risk — Pipeline: zovegalisib; Quality below floor (1.5 < 4.0); Value-trap signals (2/5): Material insider selling (17 sells, 0.06% of cap), Negative free cash flow.
Relay Therapeutics, Inc. trades at a P/E of N/A (forward -8.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
18 analysts cover RLAY with a consensus score of 4.4/5. Average price target: $21.
What does Relay Therapeutics, Inc. do?Relay Therapeutics is a clinical-stage precision oncology company using its Dynamo Motion-Based Drug Design platform to...
Relay Therapeutics is a clinical-stage precision oncology company using its Dynamo Motion-Based Drug Design platform to develop small molecule inhibitors for cancer. The lead candidate zovegalisib (RLY-2608) is the first allosteric pan-mutant PI3Ka inhibitor, granted FDA Breakthrough Therapy Designation in February 2026, with a global Phase 3 registrational trial (ReDiscover-2) underway for HR+/HER2- advanced breast cancer. The company has no approved products and no revenue from product sales.